Loading…
Pharmaceuticals · NSE · period ending 2026-03-31
Loading chart…
✓ Core business is permissible and non-compliant income is 0% of revenue (limit 5%).
| Ratio | Value | Limit | Result |
|---|---|---|---|
| Interest-bearing debt / market cap | 0% | < 30% | Pass |
| Interest-bearing investments / market cap | 0% | < 30% | Pass |
The underlying figures and the filing citations they came from are available with a free account.
Sign up free0% of any dividend from SUNPHARMA should be given to charity. Calculate your amount →
SUNPHARMA shows small mixed returns with modest 6-month gains, slight recent declines, and sits close to its 52-week high. The 50-day above the 200-day hints at a gentle upward bias, but muted moves overall are consistent with a mainly range-bound phase.
Computed from delayed price history and desk sentiment. Educational context only — not investment advice or a price prediction.
Compliance watch: verdict re-verified against live market cap on 13 Jun 2026 · rechecked every 6 hours · filings reviewed quarterly.